$18.60
-0.17-0.91%
Last update: 6:58 PM
15 minutes delayed
Comments
Loading...
NovoCure
NVCRNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
NovoCure (NASDAQ:NVCR) Stock, Analyst Ratings, Price Targets, Forecasts
NovoCure Ltd has a consensus price target of $76.17 based on the ratings of 13 analysts. The high is $200 issued by Loop Capital on February 8, 2022. The low is $17 issued by JP Morgan on March 19, 2024. The 3 most-recent analyst ratings were released by Evercore ISI Group, HC Wainwright & Co., and HC Wainwright & Co. on July 2, 2024, June 4, 2024, and May 2, 2024, respectively. With an average price target of $21.33 between Evercore ISI Group, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 13.38% upside for NovoCure Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Evercore ISI Group
HC Wainwright & Co.
Piper Sandler
Wells Fargo
JP Morgan
1calculated from analyst ratings
Analyst Ratings for NovoCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/02/2024 | Buy Now | 6.3% | Evercore ISI Group | Vijay Kumar | $14.5 → $20 | Maintains | In-Line | Get Alert |
| 06/04/2024 | Buy Now | 16.93% | HC Wainwright & Co. | Emily Bodnar | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 05/02/2024 | Buy Now | 16.93% | HC Wainwright & Co. | Emily Bodnar | $24 → $22 | Maintains | Neutral | Get Alert |
| 04/10/2024 | Buy Now | 48.82% | Piper Sandler | Jason Bednar | $25 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | 123.23% | Wells Fargo | Larry Biegelsen | $49 → $42 | Maintains | Overweight | Get Alert |
| 03/27/2024 | Buy Now | 27.56% | HC Wainwright & Co. | Emily Bodnar | $22 → $24 | Maintains | Neutral | Get Alert |
| 03/19/2024 | Buy Now | -9.65% | JP Morgan | Jessica Fye | $15 → $17 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | 16.93% | HC Wainwright & Co. | Emily Bodnar | → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | -20.28% | Evercore ISI Group | Vijay Kumar | $14 → $15 | Maintains | In-Line | Get Alert |
| 02/22/2024 | Buy Now | 16.93% | HC Wainwright & Co. | Emily Bodnar | $21 → $22 | Maintains | Buy | Get Alert |
| 08/29/2023 | Buy Now | 160.43% | Wells Fargo | Larry Biegelsen | $102 → $49 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | 32.87% | HC Wainwright & Co. | Emily Bodnar | → $25 | Downgrade | Buy → Neutral | Get Alert |
| 08/08/2023 | Buy Now | 139.17% | Piper Sandler | Jason Bednar | → $45 | Upgrade | Neutral → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 171.06% | SVB Leerink | Jonathan Chang | → $51 | Initiates | → Outperform | Get Alert |
| 07/31/2023 | Buy Now | 75.39% | Evercore ISI Group | Vijay Kumar | → $33 | Upgrade | Underperform → In-Line | Get Alert |
| 07/28/2023 | Buy Now | 442.12% | Wells Fargo | Larry Biegelsen | $104 → $102 | Maintains | Overweight | Get Alert |
| 07/27/2023 | Buy Now | 351.77% | HC Wainwright & Co. | Emily Bodnar | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | 229.52% | Piper Sandler | Jason Bednar | $67 → $62 | Maintains | Neutral | Get Alert |
| 06/07/2023 | Buy Now | 144.49% | Wedbush | David Nierengarten | $53 → $46 | Upgrade | Underperform → Neutral | Get Alert |
| 06/06/2023 | Buy Now | 404.92% | Truist Securities | Gregory Fraser | → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 511.21% | HC Wainwright & Co. | Emily Bodnar | → $115 | Reiterates | → Buy | Get Alert |
| 05/16/2023 | Buy Now | 452.75% | Wells Fargo | Larry Biegelsen | $70 → $104 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/05/2023 | Buy Now | 404.92% | Truist Securities | Gregory Lewis | $102 → $95 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 511.21% | HC Wainwright & Co. | Emily Bodnar | $130 → $115 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 165.75% | JP Morgan | Jessica Fye | $99 → $50 | Downgrade | Neutral → Underweight | Get Alert |
| 01/17/2023 | Buy Now | 325.19% | Piper Sandler | Jason Bednar | $70 → $80 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 426.18% | JP Morgan | Jessica Fye | $86 → $99 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 468.7% | Wells Fargo | Larry Biegelsen | $89 → $107 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | 373.03% | Wells Fargo | Larry Biegelsen | $74 → $89 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/28/2022 | Buy Now | 442.12% | Truist Securities | Gregory Fraser | $105 → $102 | Maintains | Buy | Get Alert |
| 10/28/2022 | Buy Now | 293.3% | Wells Fargo | Larry Biegelsen | $70 → $74 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 431.49% | HC Wainwright & Co. | Emily Bodnar | $115 → $100 | Maintains | Buy | Get Alert |
| 10/24/2022 | Buy Now | 272.04% | Piper Sandler | Jason Bednar | $90 → $70 | Downgrade | Overweight → Neutral | Get Alert |
| 07/29/2022 | Buy Now | 458.07% | Truist Securities | Gregory Fraser | $118 → $105 | Maintains | Buy | Get Alert |
| 07/05/2022 | Buy Now | — | Evercore ISI Group | Vijay Kumar | — | Downgrade | In-Line → Underperform | Get Alert |
| 05/16/2022 | Buy Now | 511.21% | HC Wainwright & Co. | Emily Bodnar | → $115 | Initiates | → Buy | Get Alert |
| 05/13/2022 | Buy Now | 431.49% | Piper Sandler | Jason Bednar | $125 → $100 | Maintains | Overweight | Get Alert |
| 02/08/2022 | Buy Now | 962.98% | Loop Capital | Jason Wittes | → $200 | Initiates | → Buy | Get Alert |
| 02/02/2022 | Buy Now | 420.86% | Oppenheimer | Kevin DeGeeter | → $98 | Upgrade | Perform → Outperform | Get Alert |
| 01/20/2022 | Buy Now | — | Truist Securities | Gregg Gilbert | — | Upgrade | Hold → Buy | Get Alert |
| 01/11/2022 | Buy Now | 272.04% | Wells Fargo | Larry Biegelsen | $105 → $70 | Maintains | Equal-Weight | Get Alert |
| 01/03/2022 | Buy Now | 335.82% | Evercore ISI Group | Vijay Kumar | → $82 | Upgrade | Underperform → In-Line | Get Alert |
| 07/30/2021 | Buy Now | 856.68% | Wells Fargo | Larry Biegelsen | — | Maintains | Equal-Weight | Get Alert |
| 07/30/2021 | Buy Now | 962.98% | Mizuho | Difei Yang | — | Maintains | Neutral | Get Alert |
FAQ
What is the target price for NovoCure (NVCR) stock?
The latest price target for NovoCure (NASDAQ:NVCR) was reported by Evercore ISI Group on July 2, 2024. The analyst firm set a price target for $20.00 expecting NVCR to rise to within 12 months (a possible 7.53% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NovoCure (NVCR)?
The latest analyst rating for NovoCure (NASDAQ:NVCR) was provided by Evercore ISI Group, and NovoCure maintained their in-line rating.
When was the last upgrade for NovoCure (NVCR)?
The last upgrade for NovoCure Ltd happened on August 8, 2023 when Piper Sandler raised their price target to $45. Piper Sandler previously had a neutral for NovoCure Ltd.
When was the last downgrade for NovoCure (NVCR)?
The last downgrade for NovoCure Ltd happened on August 28, 2023 when HC Wainwright & Co. changed their price target from N/A to $25 for NovoCure Ltd.
When is the next analyst rating going to be posted or updated for NovoCure (NVCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on July 2, 2024 so you should expect the next rating to be made available sometime around July 2, 2025.
Is the Analyst Rating NovoCure (NVCR) correct?
While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a maintained with a price target of $14.50 to $20.00. The current price NovoCure (NVCR) is trading at is $18.60, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.